Kineta Past Earnings Performance

Past criteria checks 0/6

Kineta's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 100% per year.

Key information

-23.3%

Earnings growth rate

-18.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-100.0%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Kineta makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:KANT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-21100
31 Mar 245-18120
31 Dec 235-14120
30 Sep 236-58130
30 Jun 236-5913-7
31 Mar 232-65110
31 Dec 222-6390
30 Sep 223-2074
30 Jun 225-17615
31 Mar 227-14512
31 Dec 219-12516
31 Dec 2010-849

Quality Earnings: KANT is currently unprofitable.

Growing Profit Margin: KANT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KANT is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.

Accelerating Growth: Unable to compare KANT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KANT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: KANT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies